ArticleJournal of clinical medicine2020
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Prognostic superiority of volumetric PET parameters (MTV and TLG) over SUV in advanced non-small-cell lung cancer: a systematic review and meta-analysis of univariate and multivariate evidence.Frontiers in immunology · 2026Pooled it
- Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Prognostic value ofFrontiers in immunology · 2022Pooled it
- Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.International journal of cancer · 2026Trial
- Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.Journal for immunotherapy of cancer · 2025Trial
- Metabolic tumor volume onTranslational lung cancer research · 2025Article
- BaselineFrontiers in medicine · 2025Article
- Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survival.Translational lung cancer research · 2024Article
- Article
- Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([European radiology · 2024Article
- Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review.Translational lung cancer research · 2024Review
- Total metabolic tumor volume onJournal for immunotherapy of cancer · 2024Article
- Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.Oncology letters · 2024Article
- Patlak-Ki derived from ultra-high sensitivity dynamic total body [European journal of nuclear medicine and molecular imaging · 2023Article
- Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition.Journal of clinical medicine · 2023Article
- Volumetric parameters of the primary tumor and whole-body tumor burden derived from baselineEuropean journal of hybrid imaging · 2022Article
- Article
- Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.International journal of molecular sciences · 2022Review
- Molecular imaging to support cancer immunotherapy.Journal for immunotherapy of cancer · 2022Review
- Prospective assessment usingScientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It remains unclear whether the accumulation of 2-deoxy-2-[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.